BioSyent (CVE:RX) Shares Cross Above 50 Day Moving Average – Should You Sell?

BioSyent Inc. (CVE:RX)’s stock price crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of C$11.36 and traded as high as C$11.45. BioSyent shares last traded at C$11.00, with a volume of 6,223 shares traded.

BioSyent Stock Up 1.5 %

The firm has a market cap of C$129.34 million, a price-to-earnings ratio of 18.60 and a beta of 0.93. The firm has a 50 day moving average price of C$11.36 and a 200-day moving average price of C$10.75. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19.

Insider Buying and Selling at BioSyent

In other news, insider FAX Capital Corp. sold 230,800 shares of BioSyent stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Also, Senior Officer Robert Joseph March sold 4,775 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Insiders have sold 349,144 shares of company stock valued at $3,903,370 over the last quarter. Corporate insiders own 33.65% of the company’s stock.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.